Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2008 1
2009 2
2010 1
2011 1
2013 5
2014 7
2015 4
2016 7
2017 2
2018 6
2019 2
2020 6
2021 3
2022 3
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for do young yang
Search for Dooyoung Yang instead (1 results)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.
Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial.
Park C, Lee HS, Kang KW, Lee WS, Do YR, Kwak JY, Shin HJ, Kim SY, Yi JH, Lim SN, Lee JO, Yang DH, Jang H, Choi B, Lim J, Sun CH, Byun JM, Yoon SS, Koh Y. Park C, et al. Among authors: do yr. Nat Commun. 2024 Mar 30;15(1):2776. doi: 10.1038/s41467-024-47198-4. Nat Commun. 2024. PMID: 38555311 Free PMC article. Clinical Trial.
Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation.
Kim SJ, Jo JC, Yoon DH, Yang DH, Yoon SE, Lee GW, Kong JH, Park Y, Kang KW, Lee HS, Oh SY, Shin HJ, Lee WS, Choi YS, Jeong SH, Kim MK, Kang HJ, Yi JH, Lim SN, Yhim HY, Do YR, Yun HJ, Eom HS, Lee MH, Suh C, Kim WS. Kim SJ, et al. Among authors: do yr. Front Oncol. 2023 Aug 22;13:1230629. doi: 10.3389/fonc.2023.1230629. eCollection 2023. Front Oncol. 2023. PMID: 37675232 Free PMC article.
Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts.
Yi JH, Jeong SH, Kim SJ, Yoon DH, Kang HJ, Koh Y, Kim JS, Lee WS, Yang DH, Do YR, Kim MK, Yoo KH, Choi YS, Yun WJ, Park Y, Jo JC, Eom HS, Kwak JY, Shin HJ, Park BB, Yi SY, Kwon JH, Oh SY, Kim HJ, Sohn BS, Won JH, Hong DS, Lee HS, Lee GW, Suh C, Kim WS. Yi JH, et al. Among authors: do yr. Cancer Res Treat. 2023 Jan;55(1):325-333. doi: 10.4143/crt.2022.008. Epub 2022 Apr 22. Cancer Res Treat. 2023. PMID: 35468269 Free PMC article.
Clinical characteristics and prognostic factors of acquired haemophilia A in Korea.
Hyun SY, Shin HJ, Yoon SS, Moon JH, Han JJ, Yang DH, Lee WS, Bang SM, Yhim HY, Kim SH, Oh D, Do YR, Park Y, Choi CW, Lee JH, Jang JE, Kim SJ, Hwang DY, Kim JS. Hyun SY, et al. Among authors: do yr. Haemophilia. 2021 Sep;27(5):e609-e616. doi: 10.1111/hae.14370. Epub 2021 Jun 22. Haemophilia. 2021. PMID: 34156738
Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study.
Jeong SH, Kim SJ, Yoon DH, Park Y, Kang HJ, Koh Y, Lee GW, Lee WS, Yang DH, Do YR, Kim MK, Yoo KH, Choi YS, Yun HJ, Yi JH, Jo JC, Eom HS, Kwak JY, Shin HJ, Park BB, Hyun SY, Yi SY, Kwon JH, Oh SY, Kim HJ, Sohn BS, Won JH, Kim SH, Lee HS, Suh C, Kim WS. Jeong SH, et al. Among authors: do yr. Cancer Res Treat. 2022 Oct;54(4):1268-1277. doi: 10.4143/crt.2021.1168. Epub 2021 Dec 30. Cancer Res Treat. 2022. PMID: 34990525 Free PMC article.
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL).
Kim KH, Lee JH, Lee M, Kim HG, Do YR, Park Y, Oh SY, Shin HJ, Kim WS, Park SK, Kong JH, Park MR, Yang DH, Kwak JY, Kang HJ, Mun YC, Won JH. Kim KH, et al. Among authors: do yr. Cancer Res Treat. 2023 Jan;55(1):304-313. doi: 10.4143/crt.2022.004. Epub 2022 Mar 30. Cancer Res Treat. 2023. PMID: 35381164 Free PMC article. Clinical Trial.
50 results